Bayer AG performed as expected in the opening months of the year and reaffirmed its outlook for 2024 at constant currencies. CEO Bill Anderson also comments on his strategic priorities in the company’s news release: bayer.com/media/en-us/fi…

Our Q1 results are out! Listen to our CEO Bill Anderson sharing an overview of the last few months - and what's coming up in the next few weeks.

#TeamBayer begins Phase I study for a next generation prostate cancer therapy.

+++Breaking news+++ Bayer will present for the first time detailed results from Phase III studies for an investigational compound for menopause treatment at @ACOG 2024 Learn more: spr.ly/6013dToZf #WomensHealth #HealthForAll #HungerForNone

Congratulations on winning the #DFBCup! #TeamBayer is proud of you, Bayer 04 Leverkusen #ChampionsUnderTheCross #ForOurDream

"Having a clear mission is the essential step to creating an environment where people can make decisions - without having to go up through layers of management", says our CEO Bill Anderson in an interview with The Economist Impact, part of its CEO series. spr.ly/6019ewxnU

+++ #News +++ We are thrilled to announce that BlueRock Therapeutics Therapeutics cell therapy candidate for Parkinson’s disease has been granted RMAT designation, and look forward to seeing this candidate further advance in clinical trials. Learn more: bayer.com/media/en-us/ #TeamBayer

+++ #News +++ #TeamBayer and Samsung Electronics are joining forces to close the knowledge gap on the impact of sleep disturbances in menopause. Leveraging wearable tech, we're on a mission to improve women's health & quality of life. Learn more: spr.ly/6017eapuU

#TeamBayer is proud to be named one of the ten best international companies active in Ukraine and receive the International Flagship Project Award at the 3rd Ukraine Recovery Conference #URC2024 in Berlin. We remain dedicated to Ukraine's recovery 🇺🇦

**We're live** Join us right now, live on the Crop Science Linkedin page as we share our 2024 innovation update: spr.ly/60185C3lG

Join us live on Linkedin July 2nd: Petros Fassoulas, discusses with Matthias Berninger how the recent EU elections impact the Green Deal and a sustainable future in Europe. Attend here: spr.ly/6012gPGVi

#NEWS: Bayer and Charité - Universitätsmedizin Berlin kick off Berlin Center for Gene and Cell Therapies. Stefan Oelrich explains how the Center aims to bring medical innovations to patients quicker by integrating research, development & manufacturing of cell & gene therapies: spr.ly/6012grGA4

Reminder for Tuesday: You are invited to our live talk on the future of the Green Deal following the EU elections. Our speakers are Petros Fassoulas, Secretary General of the European Movement International & Matthias Berninger from Bayer. Find the event here: spr.ly/6018gA7Ys

#News: Asklepios BioPharmaceutical, Inc. (AskBio)’s investigational gene therapy AB-1005 for Parkinson’s disease secures FDA Fast Tack designation & the UK MHRA Innovation Passport. This shows the dedication to advancing innovative therapies for neurodegenerative diseases. Learn more: spr.ly/601090yCE

+++ #NEWS +++ We are pleased to announce topline results from a Phase III trial in men with metastatic hormone-sensitive #ProstateCancer (mHSPC). Learn more: bayer.com/media/en-us/ #TeamBayer

#news: Bayer submits new drug application to U.S. FDA for approval of our non-hormonal investigational compound for menopause. Learn more: spr.ly/6014cfR3k #WomensHealth #TeamBayer

+++ #NEWS+++ We are pleased to announce topline results from a Phase III study in patients with heart failure with mildly reduced or preserved ejection fraction. Learn more: bayer.com/media/en-us/ #TeamBayer #HealthForAll #HungerForNone

Bayer generated increased sales and lower earnings in the second quarter of 2024. Each business delivered a competitive performance. Read more in our latest press release: bayer.com/media/en-us/ba…

Our CEO Bill Anderson shares our first half results and the advances we’ve made on our strategy in #Q2. 90 day of progress in 90 seconds or less. Check it out! 👇

Want the inside scoop on what CGT industry experts are keeping close tabs on in 2024? Carl June, father of CAR T-cell therapy & Juergen Eckhardt, Head of Leaps by Bayer, discuss potential therapies for brain cancer & autoimmune diseases Forbes 👇 spr.ly/6011YexWz